Trump’s 2025 Prescription Drug Price Cuts: Impacts & Policy Analysis
Executive Summary In 2025, President Trump has launched the most aggressive suite of drug-pricing interventions of his political career. The centerpiece is a Most-Favored-Nation (MFN) pricing strategy, backed by a series of voluntary deals with major pharmaceutical companies and a new TrumpRx direct-to-consumer platform. These agreements: Peg many Medicaid and TrumpRx prices to those in […]
Trump’s 2025 Prescription Drug Price Cuts: Impacts & Policy Analysis Read More »







